Hubei Biocause Pharmaceutical Cash Flow Conversion Efficiency

Latest as of September 2023: 0.008x

Hubei Biocause Pharmaceutical cash flow conversion efficiency. Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) has a cash flow conversion efficiency ratio of 0.008x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥276.06 Million ≈ $40.40 Million USD) by net assets (CN¥33.70 Billion ≈ $4.93 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Hubei Biocause Pharmaceutical (2001–2023)

Cash flow conversion efficiency of Hubei Biocause Pharmaceutical from 2001 to 2023. This chart illustrates how Hubei Biocause Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Hubei Biocause Pharmaceutical for real-time trading data and today's change.

Hubei Biocause Pharmaceutical Cash Flow Conversion Ratio Explained

Hubei Biocause Pharmaceutical cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Hubei Biocause Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hubei Biocause Pharmaceutical ranked by their cash flow conversion efficiency. Also see 000627 market cap overview for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Gold.com, Inc. NYSE:GOLD	-0.076x
Bomin Electronics Co Ltd SHG:603936	0.009x
Maoye Commercial Co Ltd SHG:600828	-0.003x
Vietnam Export Import Commercial Joint Stock Bank VN:EIB	0.296x
JiShi Media Co Ltd SHG:601929	0.025x
ITMAX System Berhad KLSE:5309	0.060x
NAPCO Security Technologies Inc NASDAQ:NSSC	0.072x
Fusheng Precision Co Ltd TW:6670	0.068x

Annual Cash Flow Conversion Efficiency for Hubei Biocause Pharmaceutical (2001–2023)

The table below shows the annual cash flow conversion efficiency of Hubei Biocause Pharmaceutical from 2001 to 2023. Review 000627 free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2023-12-31	CN¥33.63 Billion ≈ $4.92 Billion	CN¥9.53 Billion ≈ $1.40 Billion	0.283x	+30.37%
2022-12-31	CN¥34.60 Billion ≈ $5.06 Billion	CN¥7.52 Billion ≈ $1.10 Billion	0.217x	+95.29%
2021-12-31	CN¥37.47 Billion ≈ $5.48 Billion	CN¥4.17 Billion ≈ $610.58 Million	0.111x	-82.02%
2020-12-31	CN¥34.59 Billion ≈ $5.06 Billion	CN¥21.42 Billion ≈ $3.13 Billion	0.619x	-25.61%
2019-12-31	CN¥34.35 Billion ≈ $5.03 Billion	CN¥28.60 Billion ≈ $4.19 Billion	0.833x	+44.56%
2018-12-31	CN¥26.01 Billion ≈ $3.81 Billion	CN¥14.98 Billion ≈ $2.19 Billion	0.576x	+3463.41%
2017-12-31	CN¥26.70 Billion ≈ $3.91 Billion	CN¥431.58 Million ≈ $63.15 Million	0.016x	+114.07%
2016-12-31	CN¥20.40 Billion ≈ $2.98 Billion	CN¥-2.34 Billion ≈ $-342.76 Million	-0.115x	-338.31%
2015-12-31	CN¥1.78 Billion ≈ $261.01 Million	CN¥-46.73 Million ≈ $-6.84 Million	-0.026x	-128.83%
2013-12-31	CN¥1.44 Billion ≈ $210.17 Million	CN¥130.53 Million ≈ $19.10 Million	0.091x	+48.97%
2012-12-31	CN¥1.54 Billion ≈ $224.96 Million	CN¥93.79 Million ≈ $13.72 Million	0.061x	+28.87%
2011-12-31	CN¥1.41 Billion ≈ $206.93 Million	CN¥66.95 Million ≈ $9.80 Million	0.047x	-66.23%
2010-12-31	CN¥1.60 Billion ≈ $234.43 Million	CN¥224.58 Million ≈ $32.86 Million	0.140x	+2.40%
2007-12-31	CN¥866.03 Million ≈ $126.73 Million	CN¥118.56 Million ≈ $17.35 Million	0.137x	-22.71%
2006-12-31	CN¥723.71 Million ≈ $105.90 Million	CN¥128.19 Million ≈ $18.76 Million	0.177x	+166.20%
2005-12-31	CN¥731.23 Million ≈ $107.00 Million	CN¥48.66 Million ≈ $7.12 Million	0.067x	-14.08%
2004-12-31	CN¥723.91 Million ≈ $105.93 Million	CN¥56.07 Million ≈ $8.20 Million	0.077x	+58.41%
2001-12-31	CN¥762.99 Million ≈ $111.65 Million	CN¥37.30 Million ≈ $5.46 Million	0.049x	--

About Hubei Biocause Pharmaceutical

SHE:000627 China Insurance - Life

Market Cap

$1.13 Billion

CN¥7.75 Billion CNY

Market Cap Rank

#8068 Global

#1773 in China

Share Price

CN¥1.58

Change (1 day)

+0.00%

52-Week Range

CN¥1.58 - CN¥1.58

All Time High

CN¥10.45